Brief intro:
- Author: Ting Cao, Changmin Shao, Xiaoyu Yu, Ruipei Xie, Chen Yang, Yulong Sun, Shaohua Yang, Wangjian He, Ye Xu, Qihui Fan, and Fangfu Ye
- Journal: Research (Wash D C)
- Doi: https://www.doi.org/10.34133/2022/9819154
- Publication Date: 2022 Feb 4
Products/Services used in the paper
Quotation shows PackGene:Different concentrations of 2:22 × 10^6 TU/mL SARS-CoV-2_del19AA-GFP pseudovirus (PackGene, China) in ECM were added into the endothelial compartment when HUVEC were cultured for 12-24 h.
Research Field:Covid-related
AAV Serotype:SARS-CoV-2_del19AA-GFP pseudovirus
Abstract
SARS-CoV-2 has caused a severe pneumonia pandemic worldwide with high morbidity and mortality. How to develop a preclinical model for recapitulating SARS-CoV-2 pathogenesis is still urgent and essential for the control of the pandemic. Here, we have established a 3D biomimetic alveolus-on-a-chip with mechanical strain and extracellular matrix taken into consideration. We have validated that the alveolus-on-a-chip is capable of recapitulating key physiological characteristics of human alveolar units, which lays a fundamental basis for viral infection studies at the organ level. Using virus-analogous chemicals and pseudovirus, we have explored virus pathogenesis and blocking ability of antibodies during viral infection. This work provides a favorable platform for SARS-CoV-2-related researches and has a great potential for physiology and pathophysiology studies of the human lung at the organ level in vitro.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
